Uterine carcinosarcoma – pro
Uterine sarcomas comprise less than 1% of gynecologic malignancies and 2% to 5% of all uterine malignancies. Studies suggest lenvitinib with pembrolizumab produces objective response rates of around 25-27%. Some studies reporting more improvement median progression-free survival (PFS) and overall survival (OS)
Qi Wendel Zhang, Jubilee Brown, Erin Crane, Yovanni Casablanca, and R. Wendel Naumann, Pembrolizumab plus lenvatinib in women with advanced or recurrent uterine carcinosarcoma. Meeting Abstract: 2025 ASCO Annual Meeting I Gynecologic Cancer May 28, 2025
Ozawa R, Nishikawa T, Yamamoto K, Shimoi T, Ishikawa M, Kato T, Yonemori K. The efficacy and safety of lenvatinib plus pembrolizumab therapy in patients with uterine carcinosarcoma. Gynecol Oncol Rep. 2024 Aug 8;55:101479. doi: 10.1016/j.gore.2024.101479. PMID: 39224816; PMCID: